Clinical Trials Logo

Clinical Trial Summary

Evaluate the effects of Suyusu (immunonutrition) in postoperative adjuvant chemotherapy for gastrointestinal cancer patients. The main endpoint of the study was the incidence of chemotherapy related adverse reactions (including bone marrow suppression, nausea and vomiting, diarrhea, and mucositis) in patients after two cycles of chemotherapy. The secondary endpoint indicators were: quality of life score (EORTC-QLQ-C30), nutritional risk score (PG-SGA, NRS2002), nutritional assessment indicators, changes in immune microenvironment, analysis of psychological status, survival time (1-year progression free survival rate), treatment tolerance (dose intensity, rate of treatment interruption, delay), etc.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06085365
Study type Interventional
Source China Medical University, China
Contact Xiujuan Qu
Phone 86-24-83282312
Email xiujuanqu@yahoo.com
Status Recruiting
Phase Phase 3
Start date July 24, 2023
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05922358 - Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors Phase 2
Recruiting NCT06152757 - BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors Early Phase 1
Terminated NCT04171141 - Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. Phase 1
Completed NCT01552291 - The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies Phase 4
Active, not recruiting NCT03833700 - A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) Phase 1
Completed NCT01640665 - Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors Phase 1
Recruiting NCT04629326 - PD-L1 Targeting Molecular Imaging of Solid Tumors N/A
Recruiting NCT05981235 - Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors Phase 1
Recruiting NCT05262335 - Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) Phase 2
Terminated NCT01648465 - Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors Phase 2
Not yet recruiting NCT06263205 - Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques N/A